Ovation's Sabril wins US panel nod for adults with refractory seizures
This article was originally published in Scrip
Executive Summary
A US FDAadvisory panel has unanimously endorsed approval of Ovation Pharmaceuticals' anti-epileptic Sabril (vigabatrin) for adults with complex partial seizures but said ophthalmological risks warrant limiting use to patients refractory to several other anticonvulsants.